DE69510858D1 - Mukosale Verabreichung von Pneumokokken-Antigenen - Google Patents

Mukosale Verabreichung von Pneumokokken-Antigenen

Info

Publication number
DE69510858D1
DE69510858D1 DE69510858T DE69510858T DE69510858D1 DE 69510858 D1 DE69510858 D1 DE 69510858D1 DE 69510858 T DE69510858 T DE 69510858T DE 69510858 T DE69510858 T DE 69510858T DE 69510858 D1 DE69510858 D1 DE 69510858D1
Authority
DE
Germany
Prior art keywords
mucosal administration
pneumococci
pneumococcal antigens
against pneumococcal
whole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69510858T
Other languages
English (en)
Other versions
DE69510858T2 (de
Inventor
David E Briles
Hong-Yin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/246,636 external-priority patent/US5965141A/en
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Application granted granted Critical
Publication of DE69510858D1 publication Critical patent/DE69510858D1/de
Publication of DE69510858T2 publication Critical patent/DE69510858T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
DE69510858T 1994-05-20 1995-05-19 Mukosale Verabreichung von Pneumokokken-Antigenen Expired - Fee Related DE69510858T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/246,636 US5965141A (en) 1991-02-15 1994-05-20 Epitopic regions of pneumococcal surface protein a
US08/312,949 US6027734A (en) 1991-02-15 1994-09-30 Mucosal administration of pneumococcal antigens

Publications (2)

Publication Number Publication Date
DE69510858D1 true DE69510858D1 (de) 1999-08-26
DE69510858T2 DE69510858T2 (de) 2000-04-13

Family

ID=26938117

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69510858T Expired - Fee Related DE69510858T2 (de) 1994-05-20 1995-05-19 Mukosale Verabreichung von Pneumokokken-Antigenen

Country Status (13)

Country Link
US (1) US6027734A (de)
EP (1) EP0682950B1 (de)
JP (1) JP2747435B2 (de)
AT (1) ATE182270T1 (de)
AU (1) AU698724B2 (de)
CA (1) CA2149703A1 (de)
DE (1) DE69510858T2 (de)
DK (1) DK0682950T3 (de)
ES (1) ES2135663T3 (de)
FI (1) FI952445A (de)
GR (1) GR3031491T3 (de)
IL (1) IL113772A0 (de)
NO (1) NO951982L (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039113A2 (en) * 1995-06-02 1996-12-12 Uab Research Foundation Oral administration of pneumococcal antigens
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
KR20060126844A (ko) * 1998-04-07 2006-12-08 메디뮨 인코포레이티드 백신용 폐렴 구균의 콜린 결합성 단백질의 유도체
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
WO2002029100A1 (en) * 2000-09-29 2002-04-11 Genomics Collaborative, Inc. Methods of diagnosing community acquired pneumonia (cap) and predisposition or susceptibility for cap and associated septic shock through detection of gene polymorphisms
US6929798B2 (en) * 2002-02-13 2005-08-16 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
EP1668112A4 (de) 2003-06-20 2009-04-29 Protein Sciences Corp Sars-immunogene exprimierende vektoren, solche vektoren oder expressionsprodukte davon enthaltende zusammensetzungen, verfahren und tests zur herstellung und verwendung
CN102861325A (zh) * 2003-11-10 2013-01-09 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
CA2661210A1 (en) * 2006-08-17 2008-02-21 The Uab Research Foundation Diagnosing pneumococcal pneumonia
WO2008143676A1 (en) 2007-05-23 2008-11-27 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
CN109289045A (zh) 2012-09-19 2019-02-01 国立大学法人大阪大学 含有肺炎球菌表面蛋白a的肺炎球菌疫苗
US11053532B2 (en) 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6444889U (de) * 1987-09-14 1989-03-17
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
EP0786521A1 (de) * 1991-02-15 1997-07-30 Uab Research Foundation Für PspA kodierende Nukleinsäure
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria
CA2116261A1 (en) * 1993-04-20 1994-10-21 David E. Briles Epitopic regions of pneumococcal surface protein a

Also Published As

Publication number Publication date
IL113772A0 (en) 1995-08-31
DE69510858T2 (de) 2000-04-13
ATE182270T1 (de) 1999-08-15
FI952445A0 (fi) 1995-05-19
EP0682950A1 (de) 1995-11-22
GR3031491T3 (en) 2000-01-31
JPH0840927A (ja) 1996-02-13
AU698724B2 (en) 1998-11-05
JP2747435B2 (ja) 1998-05-06
ES2135663T3 (es) 1999-11-01
NO951982L (no) 1995-11-21
US6027734A (en) 2000-02-22
EP0682950B1 (de) 1999-07-21
CA2149703A1 (en) 1995-11-21
NO951982D0 (no) 1995-05-19
AU2015095A (en) 1995-11-30
DK0682950T3 (da) 1999-11-29
FI952445A (fi) 1995-11-21

Similar Documents

Publication Publication Date Title
NO20015073D0 (no) Vaksiner
DE69510858T2 (de) Mukosale Verabreichung von Pneumokokken-Antigenen
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
KR890701758A (ko) 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
CA2022420A1 (en) Escherichia coli vaccine
DE69826019D1 (de) Feste dispergierende impfstoffe-zusammensetzung zur oralen verabreichung
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
WO2003059385A3 (en) Hiv vaccine and method of use
CA2330313A1 (en) Immunization against and treatment for infection by h.pylori
WO1996039113A3 (en) Oral administration of pneumococcal antigens
WO2003032917A3 (en) Hookworm vaccine
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
DK0535740T3 (da) Vaccine mod luftvejsinfektioner hos katte
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
RU95120818A (ru) Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции
Georgadze et al. Development and testing of antistaphylococcal heterogenous gamma globulin.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee